Amphorna Biosciences pairs disease-specific targeting systems such as fibrosis-related targets or tumor- and immune-related antigens with modular RNA payload designs, enabling precision gene regulation programs that can be extended across multiple indications.
Fibrosis-targeted LNP delivery is designed to reach activated fibroblasts in fibrosis lesions and tumor stroma, addressing a key limitation of liver-biased RNA delivery.
Our platform supports configurable RNA designs that can be tailored to regulate diverse disease-relevant genes and pathways, including knockdown, pathway modulation, immune regulation, or tissue repair.
Antibody-oligonucleotide conjugates can guide RNA payloads toward Tumor or Immune-Related Targets, enabling highly selective delivery and broad therapeutic potential.
Fibrosis-related ligands or tumor- and immune-antigen binding domains guide RNA payloads toward disease-relevant cells.
The RNA payload is released intracellularly to engage the intended molecular pathway.
RISC-mediated mRNA degradation can reduce the production of proteins linked to fibrosis progression, immune-related diseases, or cancer growth.